<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: design manufacture", fill: "#f5f5f5"},
{source: "2: design manufacture", target: "2: medical devices", fill: "#f5f5f5"},
{source: "2: medical devices", target: "2: entail inherent risks", fill: "#f5f5f5"},
{source: "2: design manufacture", target: "3: clinically", fill: "#e32636"},
{source: "3: clinically", target: "3: demanding circumstances with seriously ill patients", fill: "#e32636"},
{source: "3: demanding circumstances with seriously ill patients", target: "3: manufacture", fill: "#e32636"},
{source: "3: manufacture", target: "3: indefinitely", fill: "#e32636"},
{source: "3: clinically", target: "5: problems could lead", fill: "#008b8b"},
{source: "5: problems could lead", target: "5: safety alert", fill: "#008b8b"},
{source: "5: safety alert", target: "5: could ultimately", fill: "#008b8b"},
{source: "5: could ultimately", target: "5: certain cases", fill: "#008b8b"},
{source: "5: certain cases", target: "5: against us", fill: "#008b8b"},
{source: "5: against us", target: "5: associated with", fill: "#008b8b"},
{source: "5: problems could lead", target: "10: problems could", fill: "#ad6f69"},
{source: "10: problems could", target: "10: position liquidity", fill: "#ad6f69"},
{source: "10: position liquidity", target: "10: operations", fill: "#ad6f69"},
{source: "10: problems could", target: "11: face intense competition from", fill: "#3eb489"},
{source: "11: face intense competition from", target: "11: inability", fill: "#3eb489"},
{source: "11: inability", target: "11: effectively", fill: "#3eb489"},
{source: "11: effectively", target: "11: andor market new products", fill: "#3eb489"},
{source: "11: andor market new products", target: "11: technologies may prevent us from", fill: "#3eb489"},
{source: "11: technologies may prevent us from", target: "11: competitive", fill: "#3eb489"},
{source: "11: competitive", target: "11: significant", fill: "#3eb489"},
{source: "11: significant", target: "11: market penetration", fill: "#3eb489"},
{source: "11: face intense competition from", target: "21: legislative", fill: "#e3ff00"},
{source: "21: legislative", target: "21: administrative", fill: "#e3ff00"},
{source: "21: administrative", target: "21: restrictive", fill: "#e3ff00"},
{source: "21: restrictive", target: "21: reimbursement", fill: "#e3ff00"},
{source: "21: reimbursement", target: "21: thirdparty", fill: "#e3ff00"},
{source: "21: thirdparty", target: "21: containment", fill: "#e3ff00"},
{source: "21: containment", target: "21: procedures using", fill: "#e3ff00"},
{source: "21: legislative", target: "39: comprehensive system", fill: "#bcd4e6"},
{source: "39: comprehensive system", target: "39: regulations", fill: "#bcd4e6"},
{source: "39: regulations", target: "39: enforcement action", fill: "#bcd4e6"},
{source: "39: enforcement action", target: "39: equitable judgments", fill: "#bcd4e6"},
{source: "39: comprehensive system", target: "51: with companies", fill: "#062a78"},
{source: "51: with companies", target: "51: individuals", fill: "#062a78"},
{source: "51: individuals", target: "51: cannot assure", fill: "#062a78"},
{source: "51: cannot assure", target: "51: disputes on terms", fill: "#062a78"},
{source: "51: with companies", target: "START_HERE", fill: "#062a78"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Accuse</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Design_for_manufacturability">Design for manufacturability</a></td>
      <td>Design for manufacturability (also sometimes known as design for manufacturing or DFM) is the general engineering practice of designing products in such a way that they are easy to manufacture. The concept exists in almost all engineering disciplines, but the implementation differs widely depending on the manufacturing technology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gobelins_Manufactory">Gobelins Manufactory</a></td>
      <td>The Gobelins Manufactory (French: Manufacture des Gobelins) is a historic tapestry factory in Paris, France. It is located at 42 avenue des Gobelins, near Les Gobelins métro station in the 13th arrondissement of Paris.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_nationale_de_Sèvres">Manufacture nationale de Sèvres</a></td>
      <td>The Manufacture nationale de Sèvres is one of the principal European porcelain factories. It is located in Sèvres, Hauts-de-Seine, France.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Computer-aided_manufacturing">Computer-aided manufacturing</a></td>
      <td>Computer-aided manufacturing (CAM) also known as computer-aided modeling or computer-aided machining is the use of software to control machine tools in the manufacturing of work pieces. This is not the only definition for CAM, but it is the most common; CAM may also refer to the use of a computer to assist in all operations of a manufacturing plant, including planning, management, transportation and storage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_unsolved_problems_in_economics">List of unsolved problems in economics</a></td>
      <td>This is a list of some of the major unsolved problems, puzzles, or questions in economics. Some of these are theoretical in origin and some of them concern the inability of orthodox economic theory to explain an empirical observation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Dysphagia">Dysphagia</a></td>
      <td>Dysphoria (from Ancient Greek  δύσφορος (dúsphoros) 'grievous'; from  δυσ- (dus-) 'bad, difficult', and  φέρω (phérō) 'to bear') is a profound state of unease or dissatisfaction. It is the opposite of euphoria.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Insomnia">Insomnia</a></td>
      <td>An insignia (from Latin  insignia, plural of insigne 'emblem, symbol, ensign') is a sign or mark distinguishing a group, grade, rank, or function. It can be a symbol of personal power or that of an official group or governing body.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Ageusia">Ageusia</a></td>
      <td>Ageusia (from negative prefix a- and Ancient Greek γεῦσις geûsis 'taste') is the loss of taste functions of the tongue, particularly the inability to detect sweetness, sourness, bitterness, saltiness, and umami (meaning 'pleasant/savory taste'). It is sometimes confused with anosmia – a loss of the sense of smell.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Total_depravity">Total depravity</a></td>
      <td>Total depravity (also called radical corruption or pervasive depravity) is a Protestant theological doctrine derived from the concept of original sin. It teaches that, as a consequence of man's fall, every person born into the world is enslaved to the service of sin as a result of their fallen nature and, apart from the efficacious (irresistible) or prevenient (enabling) grace of God, is completely unable to choose by themselves to follow God, refrain from evil, or accept the gift of salvation as it is offered.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aphantasia">Aphantasia</a></td>
      <td>Aphantasia is the inability to voluntarily create mental images in one's mind.The phenomenon was first described by Francis Galton in 1880 but has since remained relatively unstudied. Interest in the phenomenon renewed after the publication of a study in 2015 conducted by a team led by Professor Adam Zeman of the University of Exeter.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Esports">Esports</a></td>
      <td>Sport pertains to any form of competitive physical activity or game that aims to use, maintain, or improve physical ability and skills while providing enjoyment to participants and, in some cases, entertainment to spectators. Sports can, through casual or organized participation, improve one's physical health.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition_(economics)">Competition (economics)</a></td>
      <td>In economics, competition is a scenario where different economic firms are in contention to obtain goods that are limited by varying the elements of the marketing mix: price, product, promotion and place. In classical economic thought, competition causes commercial firms to develop new products, services and technologies, which would give consumers greater selection and better products.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitive_learning">Competitive learning</a></td>
      <td>Competitive learning is a form of unsupervised learning in artificial neural networks, in which nodes compete for the right to respond to a subset of the input data. A variant of Hebbian learning, competitive learning works by increasing the specialization of each node in the network.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Health_reimbursement_account">Health reimbursement account</a></td>
      <td>A Health Reimbursement Account, formally a Health Reimbursement Arrangement (HRA), is a type of US employer-funded health benefit plan that reimburses employees for out-of-pocket medical expenses and, in limited cases, to pay for health insurance plan premiums.An HRA is not truly an account, since it does not place funds under a separate legal title. Instead, it is an agreement under which the employee can submit qualified health expenses to the employer for reimbursement.Following implementation of the Affordable Care Act, HRAs must be integrated with a qualified employer-sponsored group health insurance plan to avoid excise tax penalties.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Capitation_(healthcare)">Capitation (healthcare)</a></td>
      <td>Capitation is a payment arrangement for health care service providers. It pays a set amount for each enrolled person assigned to them, per period of time, whether or not that person seeks care.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_A">Regulation A</a></td>
      <td>In the United States under the Securities Act of 1933, any offer to sell securities must either be registered with the United States Securities and Exchange Commission (SEC) or meet certain qualifications to exempt it from such registration. Regulation A (or Reg A) contains rules providing exemptions from the registration requirements, allowing some companies to use equity crowdfunding to offer and sell their securities without having to register the securities with the SEC. Regulation A offerings are intended to make access to capital possible for small and medium-sized companies that could not otherwise bear the costs of a normal SEC registration and to allow nonaccredited investors to participate in the offering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_(European_Union)">Regulation (European Union)</a></td>
      <td>A regulation is a legal act of the European Union that becomes immediately enforceable as law in all member states simultaneously. Regulations can be distinguished from directives which, at least in principle, need to be transposed into national law.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Radio_regulation">Radio regulation</a></td>
      <td>Radio regulation refers to the regulation and licensing of radio in international law, by individual governments, and by municipalities.\n\n\n== International regulation ==\nThe International Telecommunication Union (ITU) is a specialized agency of the United Nations (UN) that is responsible for issues that concern information and communication technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_of_therapeutic_goods">Regulation of therapeutic goods</a></td>
      <td>The regulation of therapeutic goods, defined as drugs and therapeutic devices, varies by jurisdiction. In some countries, such as the United States, they are regulated at the national level by a single agency.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Queen's_Regulations">Queen's Regulations</a></td>
      <td>The Queen's Regulations (first published in 1731 and known as the King's Regulations when the monarch is a king) is a collection of orders and regulations in force in the Royal Navy, British Army, Royal Air Force, and Commonwealth Realm Forces (where the same person as on the British throne is also their separate head of state), forming guidance for officers of these armed services in all matters of discipline and personal conduct. Originally, a single set of regulations were published in one volume.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Hardware_random_number_generator">Hardware random number generator</a></td>
      <td>In computing, a hardware random number generator (HRNG) or true random number generator (TRNG) is a device that generates random numbers from a physical process, rather than by means of an algorithm.  Such devices are often based on microscopic phenomena that generate low-level, statistically random "noise" signals, such as thermal noise, the photoelectric effect, involving a beam splitter, and other quantum phenomena.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Tourism_in_Abkhazia">Tourism in Abkhazia</a></td>
      <td>Tourism in Abkhazia is possible under Georgian law for foreigners entering the occupied territory from Georgia, although Georgia cannot assure the safety inside disputed territory.\nHowever, the Abkazian beaches on the Black Sea continue to be accessible for tourists coming from the Russian side of the Abkhazia–Russia border which is not under Georgian control.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Synchroscope">Synchroscope</a></td>
      <td>In AC electrical power systems, a synchroscope is a device that indicates the degree to which two systems (generators or power networks) are synchronized with each other.For two electrical systems to be synchronized, both systems must operate at the same frequency, and the phase angle between the systems must be zero (and two polyphase systems must have the same phase sequence). Synchroscopes measure and display the frequency difference and phase angle between two power systems.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/What's_Your_Raashee?">What's Your Raashee?</a></td>
      <td>What's Your Raashee? (lit. 'What's Your Zodiac Sign?') is a 2009 Indian Hindi-language romantic comedy film written and directed by Ashutosh Gowariker.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medical_license">Medical license</a></td>
      <td>A medical license is an occupational license that permits a person to legally practice medicine. In most countries, a person must have a medical license bestowed either by a specified government-approved professional association or a government agency before he or she can practice medicine.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>BARD C R INC /NJ/      Item 1A Risk Factors          Defects or failures <font color="blue">associated with</font> our products could lead to recalls or     <font color="blue">safety alert</font>s, <font color="blue">negative publicity</font> regarding the company and <font color="blue">litigation</font> which     could <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td>The design, <font color="blue">manufacture</font> and marketing of <font color="blue">medical devices</font> of the types we     produce <font color="blue">entail inherent risks</font></td>
    </tr>
    <tr>
      <td>Our products are often used in <font color="blue">clinically</font>     <font color="blue">demanding <font color="blue">circumstances</font> with seriously ill patients</font>, and many of the medical     devices we <font color="blue">manufacture</font> and sell are implanted in the human body for long     periods of time or <font color="blue">indefinitely</font></td>
    </tr>
    <tr>
      <td>There are a number of factors that could     result in an unsafe condition, injury or death of a <font color="blue">patient with respect</font> to     products  which  we <font color="blue">manufacture</font> or sell, including component failures,     <font color="blue">manufacturing</font> flaws, unanticipated uses of our products, design defects or     inadequate  <font color="blue">disclosure</font>  of  product-related  risks  or product-related     information</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">problems could</font> lead</font> to a recall of, or <font color="blue">safety alert</font> relating to, one     or more of our products and <font color="blue">could ultimately</font> result, in <font color="blue">certain cases</font>, in     the removal from the body of these products and claims <font color="blue">against us</font> for costs     <font color="blue">associated with</font> the removal</td>
    </tr>
    <tr>
      <td>Any recall, whether voluntary or required by     the FDA or similar <font color="blue">governmental</font> <font color="blue">authorities</font> in other countries, could result     in <font color="blue"><font color="blue">significant</font> costs</font> and <font color="blue"><font color="blue">significant</font> <font color="blue">negative publicity</font></font></td>
    </tr>
    <tr>
      <td>Negative publicity,     whether  accurate or inaccurate, could reduce <font color="blue">market <font color="blue">acceptance</font></font> of our     products, result in <font color="blue">decreased product demand</font> or <font color="blue">product withdrawals</font> and harm     our ability to market our products in the future</td>
    </tr>
    <tr>
      <td>The <font color="blue">foregoing problems</font>     <font color="blue">could also</font> result in <font color="blue">product liability</font> claims being <font color="blue">brought by <font color="blue">individuals</font></font>     or <font color="blue">by groups seeking</font> to represent a class, and while we believe that many     <font color="blue">settlements</font> and <font color="blue">judgments may</font> be covered in whole or in part under our     <font color="blue">product liability</font> insurance policies, there is no guarantee that these     <font color="blue">amounts will</font> be adequate to cover the costs</td>
    </tr>
    <tr>
      <td>Moreover, in some <font color="blue">circumstances</font>     adverse events arising from or <font color="blue">associated with</font> the design, <font color="blue">manufacture</font> or     marketing of our products could result <font color="blue">in the FDA </font>suspending or delaying its     review of our <font color="blue">applications</font> for <font color="blue">new product approvals</font></td>
    </tr>
    <tr>
      <td>Any of the foregoing     <font color="blue">problems could</font> have a material adverse effect on our business, financial     position, liquidity and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We  <font color="blue">face intense competition from</font> other companies, and an <font color="blue">inability</font> to     continue to <font color="blue">effectively</font> develop, acquire and/or market <font color="blue">new products</font> and     <font color="blue"><font color="blue">technologies</font> may prevent us from</font> being <font color="blue">competitive</font>, or achieving <font color="blue">significant</font>     <font color="blue">market penetration</font> or improved operating results</td>
    </tr>
    <tr>
      <td>The medical device business is intensely <font color="blue">competitive</font> and is <font color="blue">characterized by</font>     rapid  <font color="blue">technological</font>  change</td>
    </tr>
    <tr>
      <td>Our customers consider many factors when     choosing  among  products, including product features and <font color="blue">reliability</font>,     clinical outcomes, product <font color="blue">availability</font>, price and <font color="blue">product services provided</font>     by the <font color="blue">manufacture</font>r</td>
    </tr>
    <tr>
      <td>Product <font color="blue"><font color="blue">introduction</font>s</font>, or <font color="blue">enhancements by competitors</font>     that <font color="blue">provide better</font> features or lower pricing, may make our products or     <font color="blue">proposed products obsolete</font> or less <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>As  a  result,  we  are <font color="blue">continually</font> engaged in product <font color="blue">development</font> and     improvement programs to maintain and improve our <font color="blue">competitive</font> position</td>
    </tr>
    <tr>
      <td>We     cannot, however, guarantee that we will be successful in <font color="blue">enhancing existing</font>     products or developing <font color="blue">new products</font> or <font color="blue">technologies</font> that <font color="blue">will timely</font> achieve     <font color="blue">regulatory approval</font> or receive <font color="blue">market <font color="blue">acceptance</font></font></td>
    </tr>
    <tr>
      <td>As part of our <font color="blue">competitive</font>     strategy,  we  are  also  engaged  in the <font color="blue">acquisition</font> of <font color="blue">complementary</font>     businesses, <font color="blue">technologies</font> and products to <font color="blue">facilitate</font> our future business     strategies</td>
    </tr>
    <tr>
      <td>We  cannot  assure  you  that we will be able to identify     appropriate <font color="blue">acquisition</font> candidates, consummate transactions or obtain                                          I-7     ______________________________________________________________________    [35]Table of <font color="blue">Contents       </font><font color="blue"><font color="blue">agreements</font> with</font> favorable terms</td>
    </tr>
    <tr>
      <td>Further, once a business is acquired, any     <font color="blue">inability</font> to integrate the business, failure to retain and develop its     workforce or failure to establish and maintain <font color="blue">appropriate controls could</font>     <font color="blue">adversely</font> affect our ability to realize the anticipated benefits of any     <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>If we fail to develop <font color="blue">new products</font>, enhance existing products     or identify and acquire <font color="blue">complementary</font> businesses, <font color="blue">technologies</font> and products,     or otherwise compete <font color="blue">effectively</font>, our business and results of <font color="blue">operations</font>     could be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Domestic and foreign <font color="blue">legislative</font> or <font color="blue">administrative</font> reforms resulting in     <font color="blue">restrictive</font>  <font color="blue">reimbursement</font>  practices  of  third-party payors and cost     <font color="blue">containment</font> <font color="blue">measures could</font> decrease the demand for products purchased by our     customers,  the prices that our customers are willing to pay for those     products and the number of <font color="blue">procedures using</font> our devices</td>
    </tr>
    <tr>
      <td>Our products are <font color="blue">purchased principally by hospitals</font> or <font color="blue">physicians which</font>     typically bill various third-party payors, such as <font color="blue">governmental</font> programs     (eg, Medicare and Medicaid), <font color="blue">private insurance</font> plans and <font color="blue">managed care</font>     plans, for the <font color="blue">healthcare services provided</font> to their patients</td>
    </tr>
    <tr>
      <td>The ability     of  our customers to obtain appropriate <font color="blue">reimbursement</font> for products and     services from third-party payors is critical to the success of medical     device companies because it <font color="blue">affects which products customers purchase</font> and     the prices they are willing to pay</td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement </font><font color="blue">varies by country</font> and can     <font color="blue">significant</font>ly impact the <font color="blue">acceptance</font> of <font color="blue">new technology</font></td>
    </tr>
    <tr>
      <td><font color="blue">Implementation </font>of     healthcare reforms <font color="blue">in the <font color="blue">United States </font></font>and in <font color="blue">significant</font> overseas markets     such as Germany, Japan, France and other <font color="blue">countries may limit</font> the price of or     the level at which <font color="blue">reimbursement</font> is provided for our products and <font color="blue">adversely</font>     <font color="blue">affect both</font> our <font color="blue">pricing flexibility</font> and the demand for our products</td>
    </tr>
    <tr>
      <td><font color="blue">After     </font>we develop a <font color="blue">promising new product</font>, we may find limited demand for the     product  unless  <font color="blue">reimbursement</font>  approval  is obtained <font color="blue">from private</font> and     <font color="blue">governmental</font> third-party payors prior to <font color="blue">introduction</font></td>
    </tr>
    <tr>
      <td>Major third-party payors for <font color="blue">hospital services</font> <font color="blue">in the <font color="blue">United States </font></font>and     abroad continue to work to contain healthcare costs through, among other     things, the <font color="blue">introduction</font> of cost <font color="blue">containment</font> <font color="blue">incentives</font> and closer scrutiny     of healthcare <font color="blue"><font color="blue">expenditure</font>s</font> by both private health insurers and employers</td>
    </tr>
    <tr>
      <td>For example, in an effort to decrease costs, certain hospitals and other     customers resterilize our <font color="blue">products intended</font> for a <font color="blue">single use</font> or purchase     reprocessed products from third-party reprocessors in lieu of <font color="blue">purchasing new</font>     <font color="blue">products from us</font></td>
    </tr>
    <tr>
      <td>Further <font color="blue">legislative</font> or <font color="blue">administrative</font> reforms to the US or <font color="blue">international</font>     <font color="blue">reimbursement</font> systems in a manner that <font color="blue">significant</font>ly reduces <font color="blue">reimbursement</font>     for  <font color="blue">procedures using</font> our <font color="blue">medical devices</font> or <font color="blue">denies coverage</font> for these     procedures, or adverse decisions relating to our products by administrators     of these systems in coverage or <font color="blue">reimbursement</font> issues, would have an adverse     <font color="blue">impact on</font> the <font color="blue">acceptance</font> of our products and the <font color="blue">prices which</font> our customers     are willing to pay for them</td>
    </tr>
    <tr>
      <td>These outcomes, along with cost <font color="blue">containment</font>     measures, could have a material adverse effect on our business and results     of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>An <font color="blue">interruption</font> in our ability to <font color="blue">manufacture</font> our products or an <font color="blue">inability</font>     to obtain <font color="blue">key <font color="blue">components</font></font> or <font color="blue">raw materials</font> may <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td>We <font color="blue">manufacture</font> our <font color="blue">products at <font color="blue">facilities</font> located throughout</font> the world, some     of  which  are in areas that are prone to hurricanes and other natural     <font color="blue">disasters</font></td>
    </tr>
    <tr>
      <td>In some cases, certain of our <font color="blue">key products</font> are <font color="blue">manufacture</font>d at     <font color="blue">one facility</font></td>
    </tr>
    <tr>
      <td>If an event occurred that resulted in damage to one or more of     our <font color="blue">facilities</font>, we may be unable to <font color="blue">manufacture</font> the relevant products at     previous levels or at all</td>
    </tr>
    <tr>
      <td>In addition, we purchase many of the <font color="blue">components</font>     and <font color="blue"><font color="blue">raw materials</font> used</font> in <font color="blue">manufacturing</font> our <font color="blue">products from numerous suppliers</font>     in  various  countries</td>
    </tr>
    <tr>
      <td>For reasons of quality assurance, sole source     <font color="blue">availability</font> or cost effectiveness, certain <font color="blue">components</font> and <font color="blue">raw materials</font> are     <font color="blue">available only from</font> a <font color="blue">sole supplier</font></td>
    </tr>
    <tr>
      <td>Due to the FDA’s <font color="blue">stringent <font color="blue">regulations</font></font>     and <font color="blue">requirements</font> regarding the <font color="blue">manufacture</font> of our products, we may not be     able to <font color="blue">quickly establish <font color="blue">additional</font></font> or <font color="blue">replacement sources</font> for certain     <font color="blue">components</font>  or  materials</td>
    </tr>
    <tr>
      <td>As a result, a reduction or <font color="blue">interruption</font> in     <font color="blue">manufacturing</font>,  or  an  <font color="blue">inability</font> to secure <font color="blue">alternative</font> sources of raw     materials  or  <font color="blue">components</font>, could have a material adverse effect on our     business and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>I-8     ______________________________________________________________________    [36]Table of <font color="blue">Contents       </font>We are subject to a <font color="blue">comprehensive system</font> of federal and state laws and     <font color="blue">regulations</font>, and we could be the subject of an <font color="blue"><font color="blue">enforcement</font> action</font> or face     lawsuits and monetary or <font color="blue"><font color="blue">equitable judgment</font>s</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> are <font color="blue">affected by various broad</font> state and federal healthcare,     environmental, <font color="blue">antitrust</font> and <font color="blue">employment laws</font>, including for <font color="blue">example various</font>     FDA <font color="blue">regulations</font> and the federal Anti-Kickback Statute</td>
    </tr>
    <tr>
      <td>We are subject to     <font color="blue">periodic inspections</font> to determine <font color="blue">compliance with both</font> the FDA’s Quality     System Regulation <font color="blue">requirements</font> and/or current medical device reporting     <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue">approvals by</font> the FDA can be <font color="blue">withdrawn due</font> to failure to     <font color="blue">comply with regulatory standards</font> or the occurrence of <font color="blue">unforeseen problems</font>     <font color="blue">following initial approval</font></td>
    </tr>
    <tr>
      <td>The failure to <font color="blue">comply with regulatory standards</font>     or  the  <font color="blue">discovery</font>  of  <font color="blue">previously</font>  <font color="blue">unknown problems with</font> a product or     <font color="blue">manufacture</font>r could result in FDA Form-483 notices and/or warning letters,     fines, delays or <font color="blue">suspensions</font> of regulatory clearances, seizures or recalls     of products (with the <font color="blue">attendant expenses</font>), the banning of a particular     device, an order to replace or refund the cost of any device <font color="blue">previously</font>     <font color="blue">manufacture</font>d or <font color="blue">distributed</font>, operating <font color="blue">restrictions</font> and civil or criminal     prosecution, as well as decreased sales as a result of <font color="blue">negative publicity</font>     and <font color="blue">product liability</font> claims, and could have a material adverse effect on     our business and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In  addition,  the  healthcare  industry  is <font color="blue">under scrutiny from</font> state     <font color="blue">governments</font> and the <font color="blue">federal government with respect</font> to <font color="blue">industry practices</font> in     the area of sales and marketing</td>
    </tr>
    <tr>
      <td>If our <font color="blue">promotional activities fail</font> to     comply  with the FDA’s <font color="blue">regulations</font> or <font color="blue">guidelines</font>, we may be subject to     warnings  from  the  FDA  or <font color="blue"><font color="blue">enforcement</font> action</font>s from the FDA or other     <font color="blue">enforcement</font> bodies</td>
    </tr>
    <tr>
      <td>In the recent past, medical device <font color="blue">manufacture</font>rs have     announced  that  they  have  received subpoenas from state and federal     <font color="blue">prosecutors</font> seeking <font color="blue">documents</font> related to their <font color="blue">relationships</font> with doctors</td>
    </tr>
    <tr>
      <td>If an <font color="blue"><font color="blue">enforcement</font> action</font> involving the company were to occur, it could     result in penalties and fines and/or certain <font color="blue">prohibitions</font> on our ability to     sell our products, and could have a material adverse effect on our business     and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Lawsuits by employees, customers, licensors, licensees, suppliers, business     partners, distributors, shareholders or <font color="blue">competitors with respect</font> to how we     conduct our business could be very costly and <font color="blue">could substantially disrupt</font>     our business</td>
    </tr>
    <tr>
      <td>For example, <font color="blue">Rochester Medical Corporation </font>has sued us, Tyco     Healthcare Group, LP and certain group purchasing <font color="blue">organizations</font>, alleging     that we conspired to exclude it from the urological catheter market in     violation of <font color="blue">antitrust</font> laws</td>
    </tr>
    <tr>
      <td>In certain <font color="blue">circumstances</font>, <font color="blue">antitrust</font> laws permit     <font color="blue">successful plaintiffs</font> to <font color="blue">recover treble damages</font></td>
    </tr>
    <tr>
      <td>Disputes from time to time     <font color="blue">with companies</font> or <font color="blue">individuals</font> are not uncommon, and we <font color="blue">cannot assure</font> you     that we will be able to resolve these <font color="blue">disputes on terms</font> favorable to us</td>
    </tr>
    <tr>
      <td>The     occurrence  of  an  adverse  monetary or <font color="blue">equitable judgment</font> or a large     <font color="blue">expenditure</font> in <font color="blue">connection with</font> a settlement of any of these <font color="blue">matters could</font>     have  a  material  adverse effect on our business, <font color="blue">financial position</font>,     liquidity  and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>”         We are <font color="blue">substantially dependent on patent</font> and <font color="blue">proprietary rights</font> and could     incur  <font color="blue"><font color="blue">significant</font> costs</font> defending and protecting those rights or face     <font color="blue">restrictions</font>  or  <font color="blue">additional</font>  costs in <font color="blue">connection with</font> the sale of our     products</td>
    </tr>
    <tr>
      <td>We operate in an industry <font color="blue">characterized by</font> extensive patent <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Patent <font color="blue">litigation</font> can result in <font color="blue">significant</font> damage awards (treble damages     under  certain  <font color="blue">circumstances</font>)  and <font color="blue">injunctions</font> that <font color="blue">could prevent</font> the     <font color="blue">manufacture</font> and sale of <font color="blue">affected products</font> or result in <font color="blue">significant</font> royalty     payments in order to <font color="blue">continue selling</font> the products</td>
    </tr>
    <tr>
      <td>At any given time, we     are <font color="blue">generally</font> involved as either a plaintiff or a <font color="blue">defendant</font> in a number of     <font color="blue">patent infringement actions</font>, the outcomes of which may not be known for     <font color="blue">prolonged periods</font> of time</td>
    </tr>
    <tr>
      <td>While it is not possible to predict the outcome     of patent <font color="blue">litigation</font> incident to our business, we believe that an adverse     outcome  <font color="blue">associated with</font> any pending <font color="blue">litigation</font> could <font color="blue">generally</font> have a     material adverse effect on our business and results of <font color="blue">operations</font> in a     <font color="blue">future period</font></td>
    </tr>
    <tr>
      <td>We  rely  on a <font color="blue">combination</font> of patents, trade secrets and non<font color="blue">disclosure</font>     <font color="blue">agreements</font>  to  protect our <font color="blue">proprietary <font color="blue">intellectual property</font></font> and will     continue to do so</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that these patents, trade secrets     and non<font color="blue">disclosure</font> <font color="blue">agreements</font> will protect our <font color="blue">intellectual property</font>, but we     <font color="blue">will defend against threats</font> to our <font color="blue">intellectual property</font> to the fullest     extent</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that our pending patent <font color="blue">applications</font> will     result in <font color="blue">patents issuing</font> to us, that <font color="blue">patents issued</font> to or <font color="blue">licensed by us</font> in     the past or in the <font color="blue">future will</font> not be                                          I-9     ______________________________________________________________________    [37]Table of <font color="blue">Contents       </font>challenged or <font color="blue">circumvented by competitors</font> or that these <font color="blue">patents will</font> be     found to be valid or <font color="blue">sufficiently broad</font> to protect our freedom to operate or     to <font color="blue">provide us with</font> a <font color="blue">competitive</font> advantage</td>
    </tr>
    <tr>
      <td>In addition, we operate in     <font color="blue">foreign markets</font> where protection or <font color="blue">enforcement</font> of <font color="blue">intellectual property</font>     rights  may be <font color="blue">weaker than</font> in the United States, and inadequate patent     protection in those markets may <font color="blue">adversely</font> affect our <font color="blue">competitive</font> position</td>
    </tr>
    <tr>
      <td>Third parties <font color="blue">could also</font> obtain patents that may require us to negotiate     licenses to conduct our business, and we <font color="blue">cannot assure</font> you that the required     licenses  would  be  <font color="blue">available on reasonable terms</font> or at all</td>
    </tr>
    <tr>
      <td>For more     information, see “<font color="blue">Legal Proceedings</font></td>
    </tr>
  </tbody>
</table>